Oncotelic Reports that It's Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma
13 févr. 2019 09h15 HE
|
Oncotelic Inc
Phase 2 Clinical Data Presented at 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision MedicineOT-101 exhibited promising single agent clinical activity as second...
NX Development Corp. (NXDC) Launches FDA-Approved Gleolan™ (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas)
03 oct. 2018 14h50 HE
|
NX Development Corp.
Lexington, KY, Oct. 03, 2018 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company, today announced the U.S. commercial launch of its flagship product Gleolan™ (aminolevulinic...
Profiling Brain Cancers for More Targeted Treatments
22 déc. 2017 09h03 HE
|
The Jackson Laboratory
Farmington, Conn., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Roel Verhaak, Ph.D., is not beholden to the status quo. After all, his field, computational biology, didn’t exist, at least not formally, when he...
MRI Interventions to Exhibit its ClearPoint Neuro Intervention System at AANS 2014 Annual Meeting
03 avr. 2014 08h10 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., April 3, 2014 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint® Neuro Intervention System will be on exhibit at the 2014 Annual Meeting...
Importance of Real-Time MRI Guidance in Delivery of Toca 511 Gene Therapy Directly to High Grade Glioma Presented at Annual Society for Neuro-Oncology Scientific Meeting
03 déc. 2013 08h00 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced the presentation of clinical data demonstrating the precision of MRI-guided delivery of the...